ロード中...
Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells
Treatment options for TP53-mutated lymphoid tumors are very limited. In experimental models, TP53-mutated lymphomas were sensitive to direct inhibition of checkpoint kinase 1 (Chk1), a pivotal regulator of replication. We initially tested the potential of the highly specific Chk1 inhibitor SCH900776...
保存先:
| 出版年: | Oncotarget |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Impact Journals LLC
2016
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5308713/ https://ncbi.nlm.nih.gov/pubmed/27556692 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.11388 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|